Nephropathy in Fabry disease: possibilities for the radical improvement of prognosis for orphan diseases

Fomin V.V.; Pulin A.A.; Mukhin N.A.

doi:https://doi.org/

Fomin V.V.

I.M. Sechenov First State Moscow Medical University

Pulin A.A.

Pervyĭ MGMU im. I.M. Sechenova Minzdrava Rossii

Mukhin N.A.

GBOU VPO «Pervyj Moskovskij gosudarstvennyj meditsinskij universitet im. I.M. Sechenova», Moskva

Nephropathy in Fabry disease: possibilities for the radical improvement of prognosis for orphan diseases

Authors:

Fomin V.V., Pulin A.A., Mukhin N.A.

More about the authors

Journal: Therapeutic Archive. 2013;85(6): 4‑9

Read: 2409 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Fomin VV, Pulin AA, Mukhin NA. Nephropathy in Fabry disease: possibilities for the radical improvement of prognosis for orphan diseases. Therapeutic Archive. 2013;85(6):4‑9. (In Russ.)

Использование инфографики авторами научных работ

References:

Desnick R., Ioannou Y., Eng C. Alpha-Galactosidase A deficiency: Fabry disease. In: Scriver C.R., Sly W.S., Valle D. ed. The Metabolic and Molecular Bases of Inherited Disease. 8th ed. New York: McGraw-Hill; 2001: 3733-3774.
Fomin V.V., Pulin A.A., Aksenova O.A. i dr. Tyazheloe porazhenie podotsitov, vyyavlennoe pri elektronnoi mikroskopii pochechnogo bioptata, u patsienta s bolezn'yu Fabri bez vyrazhennykh izmenenii mochi i pochechnoi nedostatochnosti. Klin nefrol 2012; 1: 55-58.
Kornreich R., Desnick R.J., Bishop D.F. Nucleotide sequence of the human alphagalactosidase A gene. Nucleic Acids Res 1989; 17: 3301-3302.
Bishop D.F., Calhoun D.H., Bernstein H.S. et al. Human alpha-galactosidase A: nucleotide sequence of a cDNA clone encoding the mature enzyme. Proc Natl Acad Sci USA 1986; 83: 4859-4863.
Germain D. Fabry disease. Orphanet J Rare Dis 2010:5(1):30.
Elstein D., Schachamorov E., Beeri R., Altarescu G. X-inactivation in Fabry disease. Gene 2012; 505 (2): 266-268.
Ortiz A., Cianciaruso B., Cizmarik M. et al. End-stage renal disease in patients with Fabry disease: natural history data from the Fabry Registry. Nephrol Dial Transplant 2010; 25: 769-775.
Ichinose M., Nakayama M., Ohashi T. et al. Significance of screening for Fabry disease among male dialysis patients. Clin Exp Nephrol 2005; 9 (3): 228-232.
Schiffmann R., Warnock D.G., Banikazemi M. et al. Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy. Nephrol Dial Transplant 2009; 24: 2102-2111.
Branton M.H., Schiffmann R., Sabnis S.G. et al. Natural history of Fabry renal disease: influence of α-galactosidase A activity and genetic mutations on clinical course. Medicine (Baltimore) 2002; 81: 122-138.
West M., Nicholls K., Mehta A. et al. Agalsidase alfa and kidney dysfunction in Fabry disease. J Am Soc Nephrol 2009; 20: 1132-1139.
Schiffmann R., Warnock D.G., Banikazemi M. et al. Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy. Nephrol Dial Transplant 2009; 24: 2102-2111.
Whybra C., Miebach E., Mengel E. et al. A 4-year study of the efficacy and tolerability of enzyme replacement therapy with agalsidase alfa in 36 women with Fabry disease. Genet Med 2009; 11: 441-449.
Mehta A., West M.L., Pintos-Morell G. et al. Therapeutic goals in the treatment of Fabry disease. Genetic Med 2010; 12 (11): 713-720.
Bekri S., Lidove O., Jaussaud R. et al. The role of ceramide trihexoside (globotriaosylceramide) in the diagnosis and follow-up of the efficacy of treatment of Fabry disease: a review of the literature. Cardiovasc Hematol Agents Med Chem 2006; 4: 289-297.
Ortiz A., Oliviero J.P., Waldek S. et al. Nephropathy in males and females with Fabry disease: cross-sectional description of patients before treatment with enzyme replacement therapy. Nephrol Dial Transplant 2008; 23: 1600-1607.
Warnock D.G., Ortiz A., Mauer M. et al. Renal outcomes of agalsidase beta treatment for Fabry disease: role of proteinuria and timing of treatment initiation. Nephrol Dial Transplant 2012; 27 (3): 1042-1049.
Fogo A.B., Bostad L., Svarstad E. et al. Scoring system for renal pathology in Fabry disease: report of the International Study Group of Fabry Nephropathy (ISFGN). Nephrol Dial Transplant 2010; 25 (7): 2168-2177.
Najafian B., Mauer M., Hopkin R.J., Svarstad E. Renal complications of Fabry disease in children. Pediatr Nephrol 2013; 28 (5): 679-687.
Pagni F., Pieruzzi F., Zannella S. et al. Possible pathogenetic relationship between Fabry disease and renal cell carcinoma. Am J Nephrol 2012; 36 (6): 537-541.
Müller K.B., Galdieri L.C., Pereira V.G. et al. Evaluation of oxidative stress markers and cardiovascular risk factors in Fabry Disease patients. Genet Mol Biol 2012; 35 (2): 418-423.
Lee M.H., Choi E.N., Jeon Y.J., Jung S.C. Possible role of transforming growth factor-Β1 and vascular endothelial growth factor in Fabry disease nephropathy. Int J Mol Med 2012; 30 (6): 1275-1280.
Nakao S., Kodama C., Takenaka T. et al. Fabry disease: detection of undiagnosed hemodialysis patients and identification of a "renal variant" phenotype. Kidney Int 2003; 64 (3): 801-807.
Kotanko P., Kramar R., Devrnja D. et al. Results of a nationwide screening for Anderson-Fabry disease among dialysis patients. J Am Soc Nephrol 2004; 15 (5): 1323-1329.
Tanaka M., Ohashi T., Kobayashi M. et al. Identification of Fabry's disease by the screening of alpha-galactosidase A activity in male and female hemodialysis patients. Clin Nephrol 2005; 64 (4): 281-287.
Kosch M., Koch H.G., Oliveira J.P. et al. Enzyme replacement therapy administered during hemodialysis in patients with Fabry disease. Kidney Int 2004; 66: 1279-1282.
Paull L.S., Lipinski M.J., Wilson W.G, Lipinski S.E. Female with Fabry Disease Unknowingly Donates Affected Kidney to Sister: A Call for Pre-transplant Genetic Testing. JIMD Rep 2012; 4: 1-4.
Taneda S., Honda K., Nakajima I. et al. Renal transplantation between siblings with unrecognized Fabry disease. Transplant Proc 2013; 45 (1): 115-118.
Eng C.M., Germain D.P., Banikazemi M. et al. Fabry disease: Guidelines for the evaluation and management of multi-organ system involvement. Genetic Med 2006; 8 (9): 539-548.
Mehta A., Ricci R., Widmer U. et al. Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey. Eur J Clin Invest 2004; 34: 236-242.
Tøndel C., Bostad L., Larsen K.K. et al. Agalsidase benefits renal histology in young patients with Fabry disease. J Am Soc Nephrol 2013; 24 (1): 137-148.
Pisani A., Visciano B., Roux G.D. et al. Enzyme replacement therapy in patients with Fabry disease: state of the art and review of the literature. Mol Genet Metab 2012; 107 (3): 267-275.
Tahir H., Jackson L.L., Warnock D.G. Antiproteinuric therapy and Fabry nephropathy: sustained reduction of proteinuria in patients receiving enzyme replacement therapy with agalsidase-beta. J Am Soc Nephrol 2007; 18: 2609 -2617.
Levey A.S. Clinical practice. Nondiabetic kidney disease. N Engl J Med 2002; 347: 1505-1511.
Cybulla M., Kurschat C., West M. et al. Kidney transplantation and enzyme replacement therapy in patients with Fabry disease. J Nephrol 2012 Sep 19:0. doi: 10.5301/jn.5000214. [Epub ahead of print].
Pastores G.M., Thadhani R. Advances in the management of Anderson-Fabry disease: enzyme replacement therapy. Expert Opin Biol Ther 2002; 2: 325-333.